Katie Anderson 450 450 headshot

Katie Anderson

Katie brings nearly two decades of editorial experience in business-to-business media. After earning her master’s degree in journalism, she began her career at the personal care R&D trade journal Cosmetics & Toiletries. There, she thrived on the constant flow of knowledge gained from interviewing chemists, regulatory experts, formulators and testing professionals in the field.

After nearly eight years with Cosmetics & Toiletries, Katie pursued her passion for skin physiology and ingredient science as Managing Editor of the professional esthetics brand Skin Inc. That same year, she also took on the role of Conference Director for Face and Body, where she developed and managed the event’s educational programming.

Following an acquisition, Katie was promoted to Editor-in-Chief of five professional media brands: Nailpro, Skin Inc., Beauty Launchpad, Medical Esthetics, and WellSpa 360.

Throughout her 19-year editorial career, Katie has held a variety of roles, but her passion has always been scientific editorial. She is the recipient of a bronze Folio Eddie Award for a single science article. She has frequently contributed her expertise as a guest speaker on industry podcasts, webcasts, conferences and video interviews. A lifelong learner, she enjoys the challenge of translating complex technical content into material that is both accurate and accessible.

Connect with Katie on LinkedIn: https://www.linkedin.com/in/katieanderson121/

ARTICLES BY KATIE ANDERSON

  • AI Needs Human Oversight To Better GMP Documentation
    8/12/2026

    In a Pharmaceutical Online Live discussion on building inspection-ready systems with digital documentation, panelists emphasized that AI can accelerate review, trend analysis, and inspection response, but only when governed, validated, and kept firmly under human quality oversight.

  • 6 Reasons Pharma Manufacturing Has Eyes On Puerto Rico
    8/1/2026

    Several advantages explain why Puerto Rico continues to attract pharma investment, especially as manufacturers reassess supply chain risk and look for options closer to the U.S. mainland.

  • Building AI Readiness Through Cross Collaboration
    7/22/2026

    AbbVie’s Operations Quality Assurance Innovation Accelerator offers a practical model for moving from AI enthusiasm to governed, people-centered execution.

  • Bayer Adds A Spine To Modularity For Scale Without Disruption
    7/16/2026

    Modular facility concepts offer a different path, giving manufacturers the ability to expand capacity stepwise, standardize core infrastructure, and adapt production environments as product portfolios evolve

  • 7 Facilities Pilot PreCheck for Faster Approval
    7/13/2026

    A more streamlined path to operational new pharmaceutical facilities in the U.S. may be on the horizon. Nearly a year after the PreCheck Pilot Program was introduced by the U.S. Food and Drug Administration (FDA) in August 2025, the first seven participating facilities have been announced.

  • Inside Chugai's Digital Infrastructure Strategy
    6/29/2026

    When a facility is fully automated and designed for manufacturing flexibility, it needs a digital infrastructure that pulls the systems together, reports data accurately and efficiently, and recognizes areas for continuous improvement.

  • [VIDEO] GLP-1 Manufacturing's New Bottlenecks At Multi-Ton Scale
    6/24/2026

    “At multi-ton scale, the challenge becomes less about making the molecule and more about controlling the variability of the process in this interconnected system,” explained Villain.

  • Let Your Voice Help Shape Pharma Manufacturing
    6/17/2026

    Pharmaceutical Online hosts live virtual panels with industry experts on important topics and challenges, and we want to know what topics are important to you. Please consider taking a few minutes of your time to tell us what they are.

  • Building PFMs For Scalable Manufacturing
    6/17/2026

    I sat down with Rob Hughes, Ph.D., chief scientific officer at Rectify, to learn more about how PFMs work, hear about the manufacturing considerations for the technology, and learn what lies ahead for this exciting category.

  • Can Molecular Glue Degraders Make The Undruggable Druggable?
    6/12/2026

    Neomorph CEO Phil Chamberlain explains how molecular glue degraders could expand the druggable proteome and why the modality’s small-molecule profile may matter as much as its novel mechanism.